Brain reserve and timing of clinical onset in multiple sclerosis.

IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Multiple Sclerosis Journal Pub Date : 2024-09-01 Epub Date: 2024-09-05 DOI:10.1177/13524585241272046
Maria Petracca, Serena Ruggieri, Riccardo Nistri, Ilaria Tomasso, Elena Barbuti, Valeria Pozzilli, Shalom Haggiag, Carla Tortorella, Claudio Gasperini, Carlo Pozzilli, Luca Prosperini
{"title":"Brain reserve and timing of clinical onset in multiple sclerosis.","authors":"Maria Petracca, Serena Ruggieri, Riccardo Nistri, Ilaria Tomasso, Elena Barbuti, Valeria Pozzilli, Shalom Haggiag, Carla Tortorella, Claudio Gasperini, Carlo Pozzilli, Luca Prosperini","doi":"10.1177/13524585241272046","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A latent period of variable length elapses between multiple sclerosis (MS) biological onset and the occurrence of the first clinical episode reflecting a central nervous system (CNS) demyelinating event. Factors affecting the duration of such interval are unknown.</p><p><strong>Objective: </strong>To explore whether brain reserve, which moderates the impact of structural damage along MS course, could also affect the timing of MS clinical onset.</p><p><strong>Methods: </strong>We conducted a time-to-event analysis in 326 relapsing-onset multiple sclerosis patients to ascertain the effect of brain reserve, that is, larger maximal lifetime brain growth (MLBG) estimated as intracranial volume, on the risk of an earlier disease onset. For this purpose, we carried out a Cox proportional hazards regression model stratified by sex and adjusted by site and pre-morbid MS risk factors. All patients reached the event (i.e. the disease onset) with no censored case; the age (years) at disease onset was set as the main time variable.</p><p><strong>Results: </strong>We identified a protective effect of brain reserve on the time to disease onset (HR = 0.11, 95% CI = 0.02-0.83, <i>p</i> = 0.032), unchanged when accounting for MS risk factors.</p><p><strong>Conclusion: </strong>Brain reserve might counteract the pathological mechanisms ongoing after biological initiation, thus delaying the disease overt clinical manifestation.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1290-1295"},"PeriodicalIF":4.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241272046","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A latent period of variable length elapses between multiple sclerosis (MS) biological onset and the occurrence of the first clinical episode reflecting a central nervous system (CNS) demyelinating event. Factors affecting the duration of such interval are unknown.

Objective: To explore whether brain reserve, which moderates the impact of structural damage along MS course, could also affect the timing of MS clinical onset.

Methods: We conducted a time-to-event analysis in 326 relapsing-onset multiple sclerosis patients to ascertain the effect of brain reserve, that is, larger maximal lifetime brain growth (MLBG) estimated as intracranial volume, on the risk of an earlier disease onset. For this purpose, we carried out a Cox proportional hazards regression model stratified by sex and adjusted by site and pre-morbid MS risk factors. All patients reached the event (i.e. the disease onset) with no censored case; the age (years) at disease onset was set as the main time variable.

Results: We identified a protective effect of brain reserve on the time to disease onset (HR = 0.11, 95% CI = 0.02-0.83, p = 0.032), unchanged when accounting for MS risk factors.

Conclusion: Brain reserve might counteract the pathological mechanisms ongoing after biological initiation, thus delaying the disease overt clinical manifestation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多发性硬化症的脑储备和临床发病时间。
背景:从多发性硬化症(MS)生物学发病到反映中枢神经系统(CNS)脱髓鞘事件的首次临床发作之间,存在一段长短不一的潜伏期。影响这一间歇期持续时间的因素尚不清楚:目的:探讨大脑储备是否也会影响多发性硬化症临床发病的时间:方法:我们对 326 名复发型多发性硬化症患者进行了时间到事件分析,以确定脑储备(即以颅内容积估算的终生最大脑生长量(MLBG))对提前发病风险的影响。为此,我们建立了一个按性别分层的考克斯比例危险回归模型,并根据发病部位和发病前多发性硬化症的危险因素进行了调整。所有患者都达到了发病年龄(即发病时间),没有删减病例;发病时的年龄(岁)被设定为主要时间变量:结果:我们发现脑储备对发病时间具有保护作用(HR = 0.11,95% CI = 0.02-0.83,p = 0.032),在考虑多发性硬化症风险因素后,该作用保持不变:结论:脑储备可抵消生物起病后的病理机制,从而推迟疾病的明显临床表现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Multiple Sclerosis Journal
Multiple Sclerosis Journal 医学-临床神经学
CiteScore
10.90
自引率
6.90%
发文量
186
审稿时长
3-8 weeks
期刊介绍: Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585
期刊最新文献
Cryptogenic organising pneumonia in patients treated with ocrelizumab. Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review. Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case-control study. Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies. Development and initial validation of the Cognitive Change Scale (CCS).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1